Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 333

1.

Automated Bright-Field Dual-Color In Situ Hybridization for MDM2: Interobserver Reproducibility and Correlation With Fluorescence In Situ Hybridization in a Series of Soft Tissue Consults.

Zhang G, Lanigan CP, Goldblum JR, Tubbs RR, Downs-Kelly E.

Arch Pathol Lab Med. 2016 Oct;140(10):1111-5. doi: 10.5858/arpa.2015-0249-OA.

PMID:
27684983
2.

MET and PTEN gene copy numbers and Ki-67 protein expression associate with pathologic complete response in ERBB2-positive breast carcinoma patients treated with neoadjuvant trastuzumab-based therapy.

Calhoun BC, Portier B, Wang Z, Minca EC, Budd GT, Lanigan C, Tubbs RR, Morrison LE.

BMC Cancer. 2016 Aug 30;16:695. doi: 10.1186/s12885-016-2743-x.

3.

Immunohistochemistry for BRAF V600E in the Differential Diagnosis of Hairy Cell Leukemia vs Other Splenic B-Cell Lymphomas.

Turakhia S, Lanigan C, Hamadeh F, Swerdlow SH, Tubbs RR, Cook JR.

Am J Clin Pathol. 2015 Jul;144(1):87-93. doi: 10.1309/AJCP5WVXJ2KTLODO.

PMID:
26071465
4.

Global microRNA expression profiling uncovers molecular markers for classification and prognosis in aggressive B-cell lymphoma.

Iqbal J, Shen Y, Huang X, Liu Y, Wake L, Liu C, Deffenbacher K, Lachel CM, Wang C, Rohr J, Guo S, Smith LM, Wright G, Bhagavathi S, Dybkaer K, Fu K, Greiner TC, Vose JM, Jaffe E, Rimsza L, Rosenwald A, Ott G, Delabie J, Campo E, Braziel RM, Cook JR, Tubbs RR, Armitage JO, Weisenburger DD, Staudt LM, Gascoyne RD, McKeithan TW, Chan WC.

Blood. 2015 Feb 12;125(7):1137-45. doi: 10.1182/blood-2014-04-566778. Epub 2014 Dec 10.

5.

Genomic microarray analysis on formalin-fixed paraffin-embedded material for uveal melanoma prognostication.

Minca EC, Tubbs RR, Portier BP, Wang Z, Lanigan C, Aronow ME, Triozzi PL, Singh A, Cook JR, Saunthararajah Y, Plesec TP, Schoenfield L, Cawich V, Sulpizio S, Schultz RA.

Cancer Genet. 2014 Jul-Aug;207(7-8):306-15. doi: 10.1016/j.cancergen.2014.08.005. Epub 2014 Aug 29.

PMID:
25442074
6.

Detection of immunoglobulin light-chain restriction in cutaneous B-cell lymphomas by ultrasensitive bright-field mRNA in situ hybridization.

Minca EC, Wang H, Wang Z, Lanigan C, Billings SD, Luo Y, Tubbs RR, Ma XJ.

J Cutan Pathol. 2015 Feb;42(2):82-9. doi: 10.1111/cup.12415. Epub 2014 Dec 15.

PMID:
25363373
7.

Molecular profiling of primary uveal melanomas with tumor-infiltrating lymphocytes.

Triozzi PL, Schoenfield L, Plesec T, Saunthararajah Y, Tubbs RR, Singh AD.

Oncoimmunology. 2014 Oct 31;8(10):e947169. doi: 10.4161/21624011.2014.947169. eCollection 2019.

8.

Loss of signalling via Gα13 in germinal centre B-cell-derived lymphoma.

Muppidi JR, Schmitz R, Green JA, Xiao W, Larsen AB, Braun SE, An J, Xu Y, Rosenwald A, Ott G, Gascoyne RD, Rimsza LM, Campo E, Jaffe ES, Delabie J, Smeland EB, Braziel RM, Tubbs RR, Cook JR, Weisenburger DD, Chan WC, Vaidehi N, Staudt LM, Cyster JG.

Nature. 2014 Dec 11;516(7530):254-8. doi: 10.1038/nature13765. Epub 2014 Sep 28.

9.

EGFR mutational genotyping of liquid based cytology samples obtained via fine needle aspiration (FNA) at endobronchial ultrasound of non-small cell lung cancer (NSCLC).

Reynolds JP, Tubbs RR, Minca EC, MacNamara S, Almeida FA, Ma PC, Pennell NA, Cicenia JC.

Lung Cancer. 2014 Nov;86(2):158-63. doi: 10.1016/j.lungcan.2014.09.003. Epub 2014 Sep 22.

PMID:
25263855
10.

Frequency, interobserver reproducibility and clinical significance of equivocal peaks in PCR clonality testing using Euroclonality/BIOMED-2 primers.

Park IJ, Bena J, Cotta CV, Hsi ED, Jegalian AG, Rogers HJ, Tubbs RR, Wang L, Cook JR.

J Clin Pathol. 2014 Dec;67(12):1093-8. doi: 10.1136/jclinpath-2014-202454. Epub 2014 Sep 22.

PMID:
25244911
12.

BCL2 antibodies targeted at different epitopes detect varying levels of protein expression and correlate with frequent gene amplification in diffuse large B-cell lymphoma.

Kendrick SL, Redd L, Muranyi A, Henricksen LA, Stanislaw S, Smith LM, Perry AM, Fu K, Weisenburger DD, Rosenwald A, Ott G, Gascoyne RD, Jaffe ES, Campo E, Delabie J, Braziel RM, Cook JR, Tubbs RR, Staudt LM, Chan WC, Steidl C, Grogan TM, Rimsza LM.

Hum Pathol. 2014 Oct;45(10):2144-53. doi: 10.1016/j.humpath.2014.06.005. Epub 2014 Jun 26.

13.

Gefitinib in definitive management of esophageal or gastroesophageal junction cancer: a retrospective analysis of two clinical trials.

Sohal DP, Rice TW, Rybicki LA, Rodriguez CP, Videtic GM, Saxton JP, Murthy SC, Mason DP, Phillips BE, Tubbs RR, Plesec T, McNamara MJ, Ives DI, Bodmann JW, Adelstein DJ.

Dis Esophagus. 2015 Aug-Sep;28(6):547-51. doi: 10.1111/dote.12241. Epub 2014 May 21.

PMID:
24849395
14.

ALK status testing in non-small-cell lung carcinoma by FISH on ThinPrep slides with cytology material.

Minca EC, Lanigan CP, Reynolds JP, Wang Z, Ma PC, Cicenia J, Almeida FA, Pennell NA, Tubbs RR.

J Thorac Oncol. 2014 Apr;9(4):464-8. doi: 10.1097/JTO.0000000000000104.

15.

An international interpretation study using the ALK IHC antibody D5F3 and a sensitive detection kit demonstrates high concordance between ALK IHC and ALK FISH and between evaluators.

Wynes MW, Sholl LM, Dietel M, Schuuring E, Tsao MS, Yatabe Y, Tubbs RR, Hirsch FR.

J Thorac Oncol. 2014 May;9(5):631-8. doi: 10.1097/JTO.0000000000000115.

16.
17.

Gene expression signatures delineate biological and prognostic subgroups in peripheral T-cell lymphoma.

Iqbal J, Wright G, Wang C, Rosenwald A, Gascoyne RD, Weisenburger DD, Greiner TC, Smith L, Guo S, Wilcox RA, Teh BT, Lim ST, Tan SY, Rimsza LM, Jaffe ES, Campo E, Martinez A, Delabie J, Braziel RM, Cook JR, Tubbs RR, Ott G, Geissinger E, Gaulard P, Piccaluga PP, Pileri SA, Au WY, Nakamura S, Seto M, Berger F, de Leval L, Connors JM, Armitage J, Vose J, Chan WC, Staudt LM; Lymphoma Leukemia Molecular Profiling Project and the International Peripheral T-cell Lymphoma Project.

Blood. 2014 May 8;123(19):2915-23. doi: 10.1182/blood-2013-11-536359. Epub 2014 Mar 14.

18.

Clinical significance of MYC expression and/or "high-grade" morphology in non-Burkitt, diffuse aggressive B-cell lymphomas: a SWOG S9704 correlative study.

Cook JR, Goldman B, Tubbs RR, Rimsza L, Leblanc M, Stiff P, Fisher R.

Am J Surg Pathol. 2014 Apr;38(4):494-501. doi: 10.1097/PAS.0000000000000147.

19.

Essential role of the linear ubiquitin chain assembly complex in lymphoma revealed by rare germline polymorphisms.

Yang Y, Schmitz R, Mitala J, Whiting A, Xiao W, Ceribelli M, Wright GW, Zhao H, Yang Y, Xu W, Rosenwald A, Ott G, Gascoyne RD, Connors JM, Rimsza LM, Campo E, Jaffe ES, Delabie J, Smeland EB, Braziel RM, Tubbs RR, Cook JR, Weisenburger DD, Chan WC, Wiestner A, Kruhlak MJ, Iwai K, Bernal F, Staudt LM.

Cancer Discov. 2014 Apr;4(4):480-93. doi: 10.1158/2159-8290.CD-13-0915. Epub 2014 Feb 3.

20.

Determining cell-of-origin subtypes of diffuse large B-cell lymphoma using gene expression in formalin-fixed paraffin-embedded tissue.

Scott DW, Wright GW, Williams PM, Lih CJ, Walsh W, Jaffe ES, Rosenwald A, Campo E, Chan WC, Connors JM, Smeland EB, Mottok A, Braziel RM, Ott G, Delabie J, Tubbs RR, Cook JR, Weisenburger DD, Greiner TC, Glinsmann-Gibson BJ, Fu K, Staudt LM, Gascoyne RD, Rimsza LM.

Blood. 2014 Feb 20;123(8):1214-7. doi: 10.1182/blood-2013-11-536433. Epub 2014 Jan 7.

21.

Choroidal metastases responsive to crizotinib therapy in a lung adenocarcinoma patient with ALK 2p23 fusion identified by ALK immunohistochemistry.

Feng Y, Singh AD, Lanigan C, Tubbs RR, Ma PC.

J Thorac Oncol. 2013 Dec;8(12):e109-11. doi: 10.1097/01.JTO.0000437502.82078.9b. No abstract available.

22.

Fully automated dual-color dual-hapten silver in situ hybridization staining for MYC amplification: a diagnostic tool for discriminating secondary angiosarcoma.

Ko JS, Billings SD, Lanigan CP, Buehler D, Fernandez AP, Tubbs RR.

J Cutan Pathol. 2014 Mar;41(3):286-92. doi: 10.1111/cup.12278. Epub 2014 Jan 22.

PMID:
24329959
23.

Activation of the STAT3 signaling pathway is associated with poor survival in diffuse large B-cell lymphoma treated with R-CHOP.

Huang X, Meng B, Iqbal J, Ding BB, Perry AM, Cao W, Smith LM, Bi C, Jiang C, Greiner TC, Weisenburger DD, Rimsza L, Rosenwald A, Ott G, Delabie J, Campo E, Braziel RM, Gascoyne RD, Cook JR, Tubbs RR, Jaffe ES, Armitage JO, Vose JM, Staudt LM, McKeithan TW, Chan WC, Ye BH, Fu K.

J Clin Oncol. 2013 Dec 20;31(36):4520-8. doi: 10.1200/JCO.2012.45.6004. Epub 2013 Nov 12.

24.

Autologous transplantation as consolidation for aggressive non-Hodgkin's lymphoma.

Stiff PJ, Unger JM, Cook JR, Constine LS, Couban S, Stewart DA, Shea TC, Porcu P, Winter JN, Kahl BS, Miller TP, Tubbs RR, Marcellus D, Friedberg JW, Barton KP, Mills GM, LeBlanc M, Rimsza LM, Forman SJ, Fisher RI.

N Engl J Med. 2013 Oct 31;369(18):1681-90. doi: 10.1056/NEJMoa1301077.

25.

Ultrasensitive RNA in situ hybridization for detection of restricted clonal expression of low-abundance immunoglobulin light chain mRNA in B-cell lymphoproliferative disorders.

Tubbs RR, Wang H, Wang Z, Minca EC, Portier BP, Gruver AM, Lanigan C, Luo Y, Cook JR, Ma XJ.

Am J Clin Pathol. 2013 Nov;140(5):736-46. doi: 10.1309/AJCPJTWK07FSABRJ.

PMID:
24124155
26.

HER4 expression status correlates with improved outcome in both neoadjuvant and adjuvant Trastuzumab treated invasive breast carcinoma.

Portier BP, Minca EC, Wang Z, Lanigan C, Gruver AM, Downs-Kelly E, Budd GT, Tubbs RR.

Oncotarget. 2013 Oct;4(10):1662-72.

27.

Immunoarchitectural patterns of germinal center antigens including LMO2 assist in the differential diagnosis of marginal zone lymphoma vs follicular lymphoma.

Dyhdalo KS, Lanigan C, Tubbs RR, Cook JR.

Am J Clin Pathol. 2013 Aug;140(2):149-54. doi: 10.1309/AJCPHPVH4M7MTWUN.

PMID:
23897248
28.

New guideline sets the ground rules for routine molecular testing in non-small cell lung cancer.

Pennell NA, Tubbs RR.

J Mol Diagn. 2013 Jul;15(4):413-4. doi: 10.1016/j.jmoldx.2013.05.001. No abstract available.

29.

Genome-wide methylation analyses identify a subset of mantle cell lymphoma with a high number of methylated CpGs and aggressive clinicopathological features.

Enjuanes A, Albero R, Clot G, Navarro A, Beà S, Pinyol M, Martín-Subero JI, Klapper W, Staudt LM, Jaffe ES, Rimsza L, Braziel RM, Delabie J, Cook JR, Tubbs RR, Gascoyne R, Connors JM, Weisenburger DD, Greiner TC, Chan WC, López-Guillermo A, Rosenwald A, Ott G, Campo E, Jares P.

Int J Cancer. 2013 Dec 15;133(12):2852-63. doi: 10.1002/ijc.28321. Epub 2013 Jul 16.

30.

ALK status testing in non-small cell lung carcinoma: correlation between ultrasensitive IHC and FISH.

Minca EC, Portier BP, Wang Z, Lanigan C, Farver CF, Feng Y, Ma PC, Arrossi VA, Pennell NA, Tubbs RR.

J Mol Diagn. 2013 May;15(3):341-6. doi: 10.1016/j.jmoldx.2013.01.004. Epub 2013 Mar 13.

31.

Modified array-based comparative genomic hybridization detects cryptic and variant PML-RARA rearrangements in acute promyelocytic leukemia lacking classic translocations.

Gruver AM, Rogers HJ, Cook JR, Ballif BC, Schultz RA, Batanian JR, Fesler MJ, Tubbs RR.

Diagn Mol Pathol. 2013 Mar;22(1):10-21. doi: 10.1097/PDM.0b013e31825b8326.

PMID:
23370423
32.

Automated quantitative RNA in situ hybridization for resolution of equivocal and heterogeneous ERBB2 (HER2) status in invasive breast carcinoma.

Wang Z, Portier BP, Gruver AM, Bui S, Wang H, Su N, Vo HT, Ma XJ, Luo Y, Budd GT, Tubbs RR.

J Mol Diagn. 2013 Mar;15(2):210-9. doi: 10.1016/j.jmoldx.2012.10.003. Epub 2013 Jan 8.

33.

Delay to formalin fixation 'cold ischemia time': effect on ERBB2 detection by in-situ hybridization and immunohistochemistry.

Portier BP, Wang Z, Downs-Kelly E, Rowe JJ, Patil D, Lanigan C, Budd GT, Hicks DG, Rimm DL, Tubbs RR.

Mod Pathol. 2013 Jan;26(1):1-9. doi: 10.1038/modpathol.2012.123. Epub 2012 Aug 17.

34.

Burkitt lymphoma pathogenesis and therapeutic targets from structural and functional genomics.

Schmitz R, Young RM, Ceribelli M, Jhavar S, Xiao W, Zhang M, Wright G, Shaffer AL, Hodson DJ, Buras E, Liu X, Powell J, Yang Y, Xu W, Zhao H, Kohlhammer H, Rosenwald A, Kluin P, Müller-Hermelink HK, Ott G, Gascoyne RD, Connors JM, Rimsza LM, Campo E, Jaffe ES, Delabie J, Smeland EB, Ogwang MD, Reynolds SJ, Fisher RI, Braziel RM, Tubbs RR, Cook JR, Weisenburger DD, Chan WC, Pittaluga S, Wilson W, Waldmann TA, Rowe M, Mbulaiteye SM, Rickinson AB, Staudt LM.

Nature. 2012 Oct 4;490(7418):116-20. doi: 10.1038/nature11378. Epub 2012 Aug 12.

35.

Concurrent expression of MYC and BCL2 in diffuse large B-cell lymphoma treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone.

Johnson NA, Slack GW, Savage KJ, Connors JM, Ben-Neriah S, Rogic S, Scott DW, Tan KL, Steidl C, Sehn LH, Chan WC, Iqbal J, Meyer PN, Lenz G, Wright G, Rimsza LM, Valentino C, Brunhoeber P, Grogan TM, Braziel RM, Cook JR, Tubbs RR, Weisenburger DD, Campo E, Rosenwald A, Ott G, Delabie J, Holcroft C, Jaffe ES, Staudt LM, Gascoyne RD.

J Clin Oncol. 2012 Oct 1;30(28):3452-9. Epub 2012 Jul 30.

36.

Diagnosis of BK viral nephropathy in the renal allograft biopsy: role of fluorescence in situ hybridization.

Wang Z, Portier BP, Hu B, Chiesa-Vottero A, Myles J, Procop GW, Tubbs RR.

J Mol Diagn. 2012 Sep;14(5):494-500. doi: 10.1016/j.jmoldx.2012.04.004. Epub 2012 Jul 5.

37.

Clinicopathologic features and treatment outcomes of patients with human epidermal growth factor receptor 2-positive adenocarcinoma of the esophagus and gastroesophageal junction.

Phillips BE, Tubbs RR, Rice TW, Rybicki LA, Plesec T, Rodriguez CP, Videtic GM, Saxton JP, Ives DI, Adelstein DJ.

Dis Esophagus. 2013 Apr;26(3):299-304. doi: 10.1111/j.1442-2050.2012.01369.x. Epub 2012 Jun 7.

PMID:
22676551
38.

Solitary fibrous tumor: is there a molecular relationship with cellular angiofibroma, spindle cell lipoma, and mammary-type myofibroblastoma?

Fritchie KJ, Carver P, Sun Y, Batiouchko G, Billings SD, Rubin BP, Tubbs RR, Goldblum JR.

Am J Clin Pathol. 2012 Jun;137(6):963-70. doi: 10.1309/AJCPQEG6YNN6CNAL.

PMID:
22586056
39.

Chromosome 3 status in uveal melanoma: a comparison of fluorescence in situ hybridization and single-nucleotide polymorphism array.

Singh AD, Aronow ME, Sun Y, Bebek G, Saunthararajah Y, Schoenfield LR, Biscotti CV, Tubbs RR, Triozzi PL, Eng C.

Invest Ophthalmol Vis Sci. 2012 Jun 5;53(7):3331-9. doi: 10.1167/iovs.11-9027.

40.

From morphologic to molecular: established and emerging molecular diagnostics for breast carcinoma.

Portier BP, Gruver AM, Huba MA, Minca EC, Cheah AL, Wang Z, Tubbs RR.

N Biotechnol. 2012 Sep 15;29(6):665-81. doi: 10.1016/j.nbt.2012.03.011. Epub 2012 Apr 6. Review.

PMID:
22504737
41.

Genome-wide miRNA profiling of mantle cell lymphoma reveals a distinct subgroup with poor prognosis.

Iqbal J, Shen Y, Liu Y, Fu K, Jaffe ES, Liu C, Liu Z, Lachel CM, Deffenbacher K, Greiner TC, Vose JM, Bhagavathi S, Staudt LM, Rimsza L, Rosenwald A, Ott G, Delabie J, Campo E, Braziel RM, Cook JR, Tubbs RR, Gascoyne RD, Armitage JO, Weisenburger DD, McKeithan TW, Chan WC.

Blood. 2012 May 24;119(21):4939-48. doi: 10.1182/blood-2011-07-370122. Epub 2012 Apr 5.

42.

BRAF-mutated, microsatellite-stable adenocarcinoma of the proximal colon: an aggressive adenocarcinoma with poor survival, mucinous differentiation, and adverse morphologic features.

Pai RK, Jayachandran P, Koong AC, Chang DT, Kwok S, Ma L, Arber DA, Balise RR, Tubbs RR, Shadrach B, Pai RK.

Am J Surg Pathol. 2012 May;36(5):744-52. doi: 10.1097/PAS.0b013e31824430d7.

43.

Gamma heavy-chain disease: defining the spectrum of associated lymphoproliferative disorders through analysis of 13 cases.

Bieliauskas S, Tubbs RR, Bacon CM, Eshoa C, Foucar K, Gibson SE, Kroft SH, Sohani AR, Swerdlow SH, Cook JR.

Am J Surg Pathol. 2012 Apr;36(4):534-43. doi: 10.1097/PAS.0b013e318240590a.

44.

The expanded histologic spectrum of myxoid liposarcoma with an emphasis on newly described patterns: implications for diagnosis on small biopsy specimens.

Fritchie KJ, Goldblum JR, Tubbs RR, Sun Y, Carver P, Billings SD, Rubin BP.

Am J Clin Pathol. 2012 Feb;137(2):229-39. doi: 10.1309/AJCP90YNOKBAGCDM.

PMID:
22261448
45.

FISH for MYC amplification and anti-MYC immunohistochemistry: useful diagnostic tools in the assessment of secondary angiosarcoma and atypical vascular proliferations.

Fernandez AP, Sun Y, Tubbs RR, Goldblum JR, Billings SD.

J Cutan Pathol. 2012 Feb;39(2):234-42. doi: 10.1111/j.1600-0560.2011.01843.x. Epub 2011 Nov 29.

PMID:
22121953
46.

Evaluation of chronic lymphocytic leukemia by oligonucleotide-based microarray analysis uncovers novel aberrations not detected by FISH or cytogenetic analysis.

Kolquist KA, Schultz RA, Slovak ML, McDaniel LD, Brown TC, Tubbs RR, Cook JR, Theil KS, Cawich V, Valentin C, Minier S, Neill NJ, Byerly S, Morton SA, Sahoo T, Ballif BC, Shaffer LG.

Mol Cytogenet. 2011 Nov 16;4:25. doi: 10.1186/1755-8166-4-25.

47.

Uveal melanoma: prognostication.

Turell ME, Tubbs RR, Biscotti CV, Singh AD.

Monogr Clin Cytol. 2012;21:55-60. doi: 10.1159/000331035. Epub 2011 Oct 18. No abstract available.

PMID:
22024584
48.

High false-negative rate of HER2 quantitative reverse transcription polymerase chain reaction of the Oncotype DX test: an independent quality assurance study.

Dabbs DJ, Klein ME, Mohsin SK, Tubbs RR, Shuai Y, Bhargava R.

J Clin Oncol. 2011 Nov 10;29(32):4279-85. doi: 10.1200/JCO.2011.34.7963. Epub 2011 Oct 11.

PMID:
21990395
49.

BCL2 predicts survival in germinal center B-cell-like diffuse large B-cell lymphoma treated with CHOP-like therapy and rituximab.

Iqbal J, Meyer PN, Smith LM, Johnson NA, Vose JM, Greiner TC, Connors JM, Staudt LM, Rimsza L, Jaffe E, Rosenwald A, Ott G, Delabie J, Campo E, Braziel RM, Cook JR, Tubbs RR, Gascoyne RD, Armitage JO, Weisenburger DD, Chan WC.

Clin Cancer Res. 2011 Dec 15;17(24):7785-95. doi: 10.1158/1078-0432.CCR-11-0267. Epub 2011 Sep 20.

50.

Co-amplification of the HER2 gene and chromosome 17 centromere: a potential diagnostic pitfall in HER2 testing in breast cancer.

Varga Z, Tubbs RR, Wang Z, Sun Y, Noske A, Kradolfer D, Bosshard G, Jochum W, Moch H, Öhlschlegel C.

Breast Cancer Res Treat. 2012 Apr;132(3):925-35. doi: 10.1007/s10549-011-1642-8. Epub 2011 Jun 23.

PMID:
21698407

Supplemental Content

Loading ...
Support Center